Studies immune and viral reservoir factors in people with HIV and persistent low-level viremia
Compares viral reservoir cells in adults with HIV who have persistent low-level virus on treatment.
Plain-language title generated from the registry record
Registry title: Role of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia Persistent Viremia in People Living With HIV on Antiretroviral Therapy
Key facts
- Where
- Paris, FranceSee the site
Where in France
- Hôpital Bichat, service des Maladies Infectieuses et TropicalesParis, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT07015164
- Record updated
- 11 June 2025
- Original description
Low-level HIV replication in a patient on effective antiretroviral therapy is a relatively frequent event, generating stress for both patient and physician, due to the fear of subsequent virological escape with emergence of resistant virus(es) and/or transmission of such virus(es) to partner(s). Understanding the origin of this low-level viral replication would enable informed therapeutic decisions to be made (therapeutic intensification, modification of antiretroviral (ARV) treatment with the use of molecules belonging to other therapeutic classes, or maintenance of the status quo), and reassure patients of the scientific rationale guiding their course of action.Read full original descriptionShow less
Role of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia Persistent Viremia in People Living With HIV on Antiretroviral Therapy
Low-level HIV replication in a patient on effective antiretroviral therapy is a relatively frequent event, generating stress for both patient and physician, due to the fear of subsequent virological escape with emergence of resistant virus(es) and/or transmission of such virus(es) to partner(s). Understanding the origin of this low-level viral replication would enable informed therapeutic decisions to be made (therapeutic intensification, modification of antiretroviral (ARV) treatment with the use of molecules belonging to other therapeutic classes, or maintenance of the status quo), and reassure patients of the scientific rationale guiding their course of action.
This is a single-center, cross-sectional study designed to compare the parameters of the cellular viral reservoir between a group of participants with persistent viral replication under ARV treatment and a group of participants with perfect viral replication control (stable virological suppression).
Patients meeting the eligibility criteria will be offered the opportunity to have two additional blood tubes taken for research purposes, as part of an integrated visit to monitor HIV infection, which already includes a venipuncture. Patients meeting these criteria will have been previously identified by a feasibility survey carried out by the clinical research team of the Infectious and Tropical Diseases Department (SMIT) at Hôpital Bichat-Claude Bernard (AP-HP. Nord).
PLHIV with persistent low plasma viral load on ARV therapy :; PLHIV > 18 years of age; On ARV treatment for at least 3 years; Taking one of the following ARV treatments:; Tenofovir Alafenamide + Emtricitabine + Bictegravir; Abacavir + Lamivudine + Dolutegravir; Tenofovir Disoproxil Fumarate + Emtricitabine + Dolutegravir; Tenofovir Disoproxil Fumarate + Lamivudine; + Doravirine; Abacavir + Lamivudine + Doravirine; With at least 3 consecutive HIV plasma viral loads between 50 and 1,000 copies/mL over a period of at least 12 months; Absence of resistance mutations to current antiretroviral treatments; PLHIV group with perfect control of viral replication (stable virological suppression):; PLWH > 18 years of age; On ARV treatment for at least 3 years; Taking one of the following ARV treatments:; Tenofovir Alafenamide + Emtricitabine + Bictegravir; Abacavir + Lamivudine + Dolutegravir; Tenofovir Disoproxil Fumarate + Emtricitabine + Dolutegravir; Tenofovir Disoproxil Fumarate + Lamivudine; + Doravirine; Abacavir + Lamivudine + Doravirine; With at least 3 plasma HIV viral loads below 50 copies/mL over a period of at least 24 months; Absence of resistance mutations to current antiretroviral treatments.